In conclusion, the findings decode a previously unidentified role for a myeloid‐TLR4 dependent Nr4a1/Ear2 negative feedback mechanism in macrophage‐mediated progressive renal injury, implying that activation of Nr4a1‐Ear2 axis can be a novel and effective immunotherapy for anti‐GBM cGN. Here, NR4A1 is linked to glioblastoma.